Mirati Therapeutics Profit Margin 2006-2021 | MRTX

Current and historical gross margin, operating margin and net profit margin for Mirati Therapeutics (MRTX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Mirati Therapeutics net profit margin as of September 30, 2021 is 0%.
Mirati Therapeutics Annual Profit Margins
Mirati Therapeutics Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.260B $0.013B
Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.655B 9.08
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.351B 19.22
Biohaven Pharmaceutical Holding (BHVN) United States $7.535B 0.00
Emergent Biosolutions (EBS) United States $2.453B 8.82
Arcus Biosciences (RCUS) United States $2.353B 0.00
Myovant Sciences (MYOV) United Kingdom $1.344B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.156B 0.00
Zymeworks (ZYME) Canada $0.627B 0.00
Ambrx Biopharma (AMAM) United States $0.207B 0.00
SQZ Biotechnologies (SQZ) United States $0.207B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81